Rare Disease Drugs Deserve Lower Cost Sharing In Part D, McClellan Says
This article was originally published in The Pink Sheet Daily
In a speech to an Oct. 24 conference on rare diseases and orphan drugs, former CMS Administrator Mark McClellan said drugs for rare disease should not be on the high-cost-sharing specialty tier of Medicare Part D formularies, which typically require coinsurance of 25% to 33%.
You may also be interested in...
In an effort to ensure that there is access to high-priced drugs that treat rare diseases, relevant stakeholders, including manufacturers, payers, patients and physicians, need to come together and collaborate on access solutions that meet the needs of all parties, Express Scripts VP of Pharma Strategies and Account Management Bill Martin tells NORD/DIA conference.
With the recent addition of claims data from two major insurance companies, the FDA postmarketing drug safety surveillance pilot project known as Mini Sentinel has already exceeded its statutory goal of gaining access to electronic health care data for 100 million individuals by July 12, 2012.
Concerns about reducing patient protections will resonate with the Biden Administration and the Medicare Part D protected classes aren’t major cost drivers anyway, Avalere’s Mendelson says.